



Nova Mentis to be Listed in the First-Ever Psychedelic Index

Vancouver, British Columbia – January 25, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that it has been included in the world’s first North American Psychedelic Index. Based on this index, The Horizon Psychedelic Stock Index ETF is expected to commence trading Jan. 27, 2021 under ticker “PSYK” on the NEO Exchange.

“NOVA is developing psilocybin and mushroom-based tryptamine derivatives for the treatment of autism spectrum disorder (ASD), an unmet medical need. We have started a preclinical study in a rat model of ASD and are planning to begin psilocybin treatment of the animals in February 2021. Submission of an IND to regulatory authorities and Phase 1 human safety studies are planned for later this year,” said Dr. Marvin S. Hausman MD, Chairman of NOVA’s Scientific Advisory Board.

“We are making important progress as we bring psychedelic research into the 21st century using current medical advancements in diagnosis, treatment, and development of objective biomarkers to confirm therapeutic responses,” he continued.

The [North American Psychedelic Stock Index](#) is provided by German-based index provider Solactive @ www.solactive.com

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. is a Canadian based biotechnology company that is focused on the emerging field of psychedelic medicine. The Company aims to become a global leader in this field by integrating the latest state-of-the-art medical and scientific technology into its drug development program. The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as Autism Spectrum Disorder (ASD).

For further information on the Company, please visit <https://www.novamentis.ca> or email info@novamentis.ca.

On Behalf of the Board

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244

Toll Free: 1-833-542-5323

Twitter: @novamentislsc

Instagram: @novamentislsc

Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.